SCHEMBL4254516

SCHEMBL4254516

CC1(C)CC(=NOC(=O)N2c3ccccc3CCc3ccccc32)CC(C)(C)N1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.55
MEN1 O00255 5/20 0.55
MAPK1 P28482 1/20 0.55
MAPT P10636 2/20 0.40
NPC1 O15118 1/20 0.40
MITF O75030 1/20 0.40
RAB9A P51151 1/20 0.40
LMNA P02545 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
NPSR1 Q6W5P4 1/20 0.37
HSD17B3 P37058 1/20 0.37
KDM4E B2RXH2 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ALDH1A1 P00352 2/20 0.36
GAA P10253 1/20 0.36
ADRB2 P07550 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4254838 0.84 MAPK1 (0.54) KMT2AMEN1MAPK1MAPTLMNA
SCHEMBL4252918 0.72 KMT2A (1.00) KMT2AMEN1MAPK1MAPTRAB9A
SCHEMBL4254557 0.68 KMT2A (0.59) KMT2AMEN1MAPK1MAPTRAB9A
SCHEMBL8436386 0.68 KMT2A (0.62) KMT2AMEN1MAPTNPC1MITF
SCHEMBL11548268 0.65 KDM4E (0.67) KMT2AMEN1NPC1MITFRAB9A
SCHEMBL31182095 0.65 KDM4E (0.67) KMT2AMEN1NPC1MITFRAB9A
SCHEMBL31182096 0.65 ALDH1A1 (0.62) KMT2AMEN1MAPK1MAPTNPC1
SCHEMBL1744688 0.65 ALDH1A1 (0.62) KMT2AMEN1MAPK1MAPTNPC1
SCHEMBL11637095 0.63 KMT2A (0.53) KMT2AMEN1MAPK1MAPTNPC1
SCHEMBL9312975 0.62 BCHE (0.58) KMT2AMEN1MAPTNPC1MITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9771331-B2 Methods of identifying neuroprotective compounds for retinal ganglion cells THE JOHNS HOPKINS UNIVERSITY (US) 2017-09-26 US disclosed
US-9771331-B2 Methods of identifying neuroprotective compounds for retinal ganglion cells THE JOHNS HOPKINS UNIVERSITY (US) 2017-09-26 US disclosed
US-9771331-B2 Methods of identifying neuroprotective compounds for retinal ganglion cells THE JOHNS HOPKINS UNIVERSITY (US) 2017-09-26 US disclosed
US-20090215765-A1 Neuroprotective compounds for treating optic neuropathies THE JOHNS HOPKINS UNIVERSITY (US) 2009-08-27 US disclosed
US-20090215765-A1 Neuroprotective compounds for treating optic neuropathies THE JOHNS HOPKINS UNIVERSITY (US) 2009-08-27 US disclosed
US-20090215765-A1 Neuroprotective compounds for treating optic neuropathies THE JOHNS HOPKINS UNIVERSITY (US) 2009-08-27 US disclosed
WO-2006116301-A1 NEUROPROTECTIVE COMPOUNDS FOR TREATING OPTIC NEUROPATHIES THE JOHNS HOPKINS UNIVERSITY (US) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215765-A1 Neuroprotective compounds for treating optic neuropathies NLN, GAP43, AIFM1 KMT2A 4656/4885MEN1 3432/4885MAPK1 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.